NCT00071981 2023-06-28
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
Clinical Trials
7 trialsNCT04703426 2023-05-22
Sargramostim (GM-CSF) + PD-1
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT00948480 2016-07-15
DCVaccineMel
Hoag Memorial Hospital Presbyterian
Phase 2 Completed
NCT00085423 2013-04-10
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00616564 2012-05-03
Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma
Mt. Sinai Medical Center, Miami
Phase 2 Completed
NCT00350597 2006-07-11
GM-CSF as Adjuvant Therapy of Melanoma
Northern California Melanoma Center
Phase 2 Completed